Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation

The cost of tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML) is a substantial economic burden. In Japan, imatinib, dasatinib, and nilotinib are now approved as first-line treatment of CML in chronic phase. Recent “stop TKI” trials have shown that TKIs can be safel...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Autores principales: Yamamoto, Chihiro, Nakashima, Hirotomo, Ikeda, Takashi, Kawaguchi, Shin-ichiro, Toda, Yumiko, Ito, Shoko, Mashima, Kiyomi, Nagayama, Takashi, Umino, Kento, Minakata, Daisuke, Nakano, Hirofumi, Morita, Kaoru, Yamasaki, Ryoko, Sugimoto, Miyuki, Ishihara, Yuko, Ashizawa, Masahiro, Hatano, Kaoru, Sato, Kazuya, Oh, Iekuni, Fujiwara, Shin-ichiro, Ueda, Masuzu, Ohmine, Ken, Muroi, Kazuo, Kanda, Yoshinobu
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2019
Materias:
Myeloid Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6855125/
https://ncbi.nlm.nih.gov/pubmed/31698458
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000745
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares